FGFR4 and hepatocellular carcinoma: Further experiments delved deeper and indicated that lenvatinib targeting of FGFR4 in liver malignancies leads to β-phosphorylation of GSK3Ser9, which contributes to the ubiquitination and degradation of PD-L1 in HCC cells [24].